Skip to content
Markets News
Stocks1 min read

FDA Clears Roche’s Wilserdly for ESR1-Mutated Breast Cancer

Makkler Newsroom
November 16, 2026 · Based on reporting by GlobeNewswire

The oral drug, used with everolimus, cut the risk of disease progression or death by 62% in a Phase III trial’s ESR1-mutated group.

Key takeaways

  • The FDA approved Wilserdly with everolimus for certain adults with ESR1-mutated advanced breast cancer.
  • In the evERA trial, the combination reduced progression or death risk by 62% versus standard endocrine therapy with everolimus.

The FDA approved Roche’s Wilserdly with everolimus for certain adults with ESR1-mutated, ER-positive, HER2-negative advanced breast cancer. The treatment is for patients whose disease returned after adjuvant endocrine therapy or progressed on at least one endocrine-based regimen.

In the Phase III evERA study, the combination reduced the risk of disease progression or death by 62% compared with standard endocrine therapy plus everolimus. The result was in patients with ESR1 mutations who had previously received a CDK4/6 inhibitor.

Roche said the all-oral regimen targets two signaling pathways and does not require injections. The FDA is also reviewing Wilserdly as an adjuvant treatment for early-stage breast cancer, with a decision expected by November 30, 2026.

Topics
ROWilserdly
Further reading

This article was produced with the help of AI technology. Based on reporting by the outlets listed above.

Comments (0)

Log in to join the discussion.Log in

No comments yet - be the first to weigh in.